| 31st week of 2010 patent applcation highlights part 41 |
| Patent application number | Title | Published |
|---|
| 20100196272 | COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN - The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce | 2010-08-05 |
| 20100196273 | NOVEL AGENT FOR IN VIVO PET IMAGING OF TUMOR PROLIFERATION - Compounds for in vivo diagnostic imaging of cellular proliferation are provided. The compounds include L-nucleosides such as a 2′-deoxy-2′-fluoro-L-ara-binofuranosyl pyrimidine nucleoside analogue. These nucleosides are labeled with a positron emitting radioisotope. The present invention also provides a method for in vivo diagnostic imaging of cellular proliferation. | 2010-08-05 |
| 20100196274 | Methods for Diagnosing Diseases and Evaluating Treatments Therefor Using Pet - The present invention relates to methods for determining whether a mammal has a disease, such as diabetes, using PET data analysis techniques. These methods include administering to a mammal a PET-compatible tracer, such as a radioligand specific for a vesicular monoamine transporter 2 (VMAT2) receptor, and measuring total functional β-cell capacity (volume) of the mammal's pancreas using PET data analysis techniques. Methods for tracking the efficacy of a treatment for diabetes, for evaluating the regeneration of β-cells in a pancreas, and for monitoring a patient with a transplanted pancreas are also provided. | 2010-08-05 |
| 20100196275 | Methods and products for neutralizing the harmful effects of combustion products - The invention relates to the role of Acr-DNA adducts in p53 mutagenesis in CS-related lung cancer. The distribution of Acr-DNA adducts was mapped at the sequence level in the p53 gene of lung cells using the UvrABC incision method in combination with ligation-mediated PCR. It was determined that Acr preferentially binds at methylated CpG sites. Also, Acr can greatly reduce the DNA repair capacity for damage induced by benzo(a)pyrene diol epoxide. Together these results suggest that Acr is a major etiological agent for CS-related lung cancer and that it contributes to lung carcinogenesis through DNA damage and inhibition of DNA repair. Methods and compositions are provided for either removing an exogenous toxic agent from a combustion product or for preventing the toxic or mutagenic effect of these toxic agents on cells and tissues. Methods are also provided for screening for candidate compounds that protect cells from toxic combustion products. | 2010-08-05 |
| 20100196276 | RECOMBINANT CANINE THYROID STIMULATING HORMONE AND METHODS OF PRODUCTION AND USE THEREOF - The invention includes a nucleic acid having a sequence at least 98% homologous to SEQ ID NO: 1, which encodes the α subunit of canine thyroid stimulating hormone (TSH). The invention also includes a nucleic acid having a sequence at least 98% homologous to SEQ ID NO: 2, which encodes the β subunit of canine TSH. The invention also includes a method of producing a recombinant canine thyroid stimulating hormone (rcTSH) subunit by expressing a nucleic acid having a sequence of SEQ ID NO: 1 and a nucleic acid having a sequence of SEQ ID NO: 2 in a transgenic insect cell modified to sialylate proteins and producing a sialylated rcTSH subunit. The insect cell may be a lepidopteran cell. The rcTSH may be used for diagnosis and treatment. It may be used to diagnose canine hypothyroidism. | 2010-08-05 |
| 20100196277 | NANOPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF NUCLEIC ACIDS - Micro- and nano-particles are molded in micro- and nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The micro- and nano-particles can include pharmaceutical compositions, biologic drugs, drug compositions, organic materials, RNA, DNA, oligonucleotides, and the like. | 2010-08-05 |
| 20100196278 | PHOTOACOUSTIC IMAGING AGENT - A molecular probe marked with a color center material is used as a photoacoustic imaging agent to obtain an acoustic signal of practically adequate intensity using weak near-infrared light, which has good in vivo penetration depth but has small excitation energy, and is within the maximum permissible exposure, in photoacoustic tomography (PAT) diagnosis of a living body. | 2010-08-05 |
| 20100196279 | TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS - Provided is a method of monitoring the treatment of Gaucher disease with specific pharmacological chaperones using systemic and/or cellular surrogate markers. Also provided is a new biomarker that may be used to monitor the progress of such treatment. | 2010-08-05 |
| 20100196280 | FUNCTIONALIZED SOLID POLYMER NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation. The cationic particle surface permits stable, electrostatic surface modification with partially oppositely charged compounds, which can contain target-specific ligands for improving passive and active targeting. | 2010-08-05 |
| 20100196281 | USE OF RESINIFERATOXIN (RTX) FOR PRODUCING AN AGENT FOR TREATING JOINT PAINS AND METHOD FOR APPLYING SAID AGENT - A method for treating a joint affected by pain that involves injecting an agent that includes resiniferatoxin (RTX) dissolved in a physiologically suitable solvent locally into the intracapsular region or the bursa of the joint affected by pain. | 2010-08-05 |
| 20100196282 | OPTICAL IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of benzopyrylium dyes with biological targeting moieties, such as peptides Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. | 2010-08-05 |
| 20100196283 | METHOD AND IMAGING MEDIUM FOR USE IN THE METHOD - The invention relates to a method of | 2010-08-05 |
| 20100196284 | Ultrasound Imaging with Targeted Microbubbles - Compositions and methods for detecting various disorders with targeted microbubbles are disclosed. Specifically, microbubbles comprising glycoprotein Ib (GPIb), ligands for VCAM-1, and ligands for P-selectin such as PSGL-1 are disclosed. Also disclosed are methods for using targeted microbubbles to detect cardiovascular disease comprising administering the disclosed microbubbles to a subject and detecting the microbubbles in the vasculature using ultrasound. | 2010-08-05 |
| 20100196285 | Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract - The present invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of virus-based diseases of the respiratory tract. | 2010-08-05 |
| 20100196286 | INHALATION DELIVERY METHODS AND DEVICES - Methods, devices and kits for treating sleep disorders, anxiety disorders, and developmental disorders, and/or for inducing an arousable state of sedation in a subject, are described. For example, inhalation methods, devices and kits for treating insomnia, anxiety and/or ADHD using one or more α2-adrenergic agonists such as dexmedetomidine or clonidine are described. | 2010-08-05 |
| 20100196287 | Compositions Comprising Perhydrolases and Alkylene Glycol Diacetates - The present invention relates to compositions, in particular washing and cleaning agents as well as cosmetic and pharmaceutical preparations, comprising perhydrolases and alkylene glycol diacetates. | 2010-08-05 |
| 20100196288 | HERBAL MIXTURE EXTRACT OF PLEUROTUS ERYNGII, ACANTHOPANACIS CORTEX AND NOTOGINSENG RADIX AND A COMPOSITION COMPRISING THE SAME FOR PREVENTION AND TREATMENT OF PERIODONTITIS - The present invention relates to a herbal mixture extract of | 2010-08-05 |
| 20100196289 | DOUBLE LAYERED OXIDE AND HYDROXIDE PIGMENTS AND METHOD OF THEIR PREPARATION - A pigment having at least two layers according to the following structure (I), where C is an internal pigment core of formula [M | 2010-08-05 |
| 20100196290 | COMPOSITIONS COMPRISING BETULONIC ACID - The invention relates to compositions of cosmetic and pharmaceutical industries comprising betulonic acid for humans and animals, and further, to the use of betulonic acid in compositions of cosmetic and pharmaceutical industries. The invention is also directed to compositions containing, besides betulonic acid, optionally other compounds derived from betulin. | 2010-08-05 |
| 20100196291 | PERSONAL CARE SUNSCREEN COMPOSITIONS HAVING REDUCED EYE IRRITATION - The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulite composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters on skin and enhanced stability. | 2010-08-05 |
| 20100196292 | Hydrophylic silicone elastomers in cosmetics - The invention is directed to the use of a number of hydrophilic silicone elastomers in various cosmetic and personal care products where they serve various functions such as emulsifiers, film forming agents, viscosity stabilizers, conditioning agents and protective barrier forming agents. Emulsions and personal care products based upon same are also described. | 2010-08-05 |
| 20100196293 | USE OF AN ACTIVE PRINCIPLE ORIGINATING FROM FLAX IN A COMPOSITION INTENDED TO REINFORCE THE BARRIER FUNCTION OF THE SKIN AND TO PROTECT THE SKIN AND THE APPENDAGES AGAINST EXTERNAL AGGRESSIONS - The present invention concerns the use, in a cosmetic composition, of an effective quantity of active principle originating from flax (genus | 2010-08-05 |
| 20100196294 | COATINGS FOR MAMMALIAN NAILS THAT INCLUDE NANOSIZED PARTICLES - One embodiment described herein includes a mammalian nail enamel. The mammalian nail enamel includes at least one film forming component; at least one plasticizer; at least one solvent; and nanoparticles of one or more of nanoclay, nanosilica, nanopigments or nanoceramics. | 2010-08-05 |
| 20100196295 | Cleansing Compositions - A composition comprising an adduct of an oil and an addition material and a flaxseed extract. | 2010-08-05 |
| 20100196296 | MULTI-LAYER METALLIC EFFECT PIGMENTS, PROCESS FOR THEIR PREPARATION AND USE - A metallic effect pigment comprising at least three layers: | 2010-08-05 |
| 20100196297 | Urine as a source of alternative cellular energy pigments (ACE-pigments) in the Assesment and therapy of diseases - Alternative cellular energy pigments (ACE-pigments) are over-produced in response to various types of viral infections and to other pathological conditions. ACE pigments accumulate at the sites of disease and also in other regions of the body, including the oral cavity. ACE pigments are considered to play a significant role in the body's healing response to both local and system diseases. They appear to exist in a relatively inactive form in which they can fluorescence under ultraviolet (UV) light illumination, especially if stained with a suitable dye, such as neutral red. The present invention describes a method of using ACE pigments collected from the urine of patients for the purpose of activating the patient's ACE pathway in a child with autism, with an extrapolation to patients with a wide variety of other infectious and non-infectious illnesses for which there is a presumed or shown insufficiency of cellular energy. Urine or urine-derived material containing the collected ACE pigments is placed onto a suitable material, such as a paper towel, stained with neutral red dye and induced to fluoresce using UV illumination. The fluorescing mixture is placed over various areas of the body and/or directly placed over a localized skin lesion and the UV illumination continued. This process will assist in the local as well as overall activation of the ACE pathway in the patient with resulting clinical benefit. | 2010-08-05 |
| 20100196298 | Coloring Materials And Their Use In Compositions, In Particular Cosmetic Compositions - The invention relates to a coloring material comprising a colored product bound to a solid substrate in which said colored product is a colored derivative of geniposide and/or genipin and/or geniposidic acid and/or an extract of a plant comprising at least one of the abovementioned products and said solid substrate is based on silicate and includes at least one metal cation. It also relates to a process for preparing this coloring material. It also relates to the use of this coloring material in the preparation of a coloring composition, in particular of a cosmetic composition, and to a method for making up the skin or superficial body growths. | 2010-08-05 |
| 20100196299 | Antiperspirant Products - Antiperspirant products are described that include a dispensing package and an antiperspirant product contained within a chamber component of the dispensing package. The portion of the chamber component that comes into contact with the antiperspirant composition is made from a polymeric resin that is substantially devoid of phosphorus compounds. | 2010-08-05 |
| 20100196300 | BASIC ALUMINUM NITRATE - A basic aluminum composition comprising an empirical formula: Al | 2010-08-05 |
| 20100196301 | HAIR CARE COMPOSITIONS - The invention provides a hair care composition comprising: (i) emulsified particles of an alkyl modified silicone, and (ii) emulsified particles of a non-volatile, non-alkyl modified silicone. The compositions are particularly suitable for use asa conditioner for the treatment of hair (typically after shampooing) and subsequent rinsing. Compositions according to the invention deliver effective conditioning to the hair, without unacceptably high deposition. | 2010-08-05 |
| 20100196302 | Keratin Hydrolysates, Process for Their Production and Cosmetic Composition Containing the Same - This present invention provides a process for keratin hydrolysis by means of microbiological and/or enzymatic processes. In particular, the keratin is derived from feathers of animals, such as chicken and are submitted to hydrolysis by a strain of | 2010-08-05 |
| 20100196303 | METHOD OF TREATING HAIR - A method of hair styling or straightening comprising: i) a straightening active selected from adenine, guanine or derivatives thereof. | 2010-08-05 |
| 20100196304 | Polyglycerol silicone polymers in personal care - The present invention relates to a series of novel silicone polyesters that are prepared by crosslinking an dimethicone copolyol, polyglycerol dimer acid. The nature of the silicone group, the water loving polyglycerol group as well as the fact that a C-36 fatty diacid is used in preparation of the products results in unique products. | 2010-08-05 |
| 20100196305 | SULFONE POLYMER COMPOSITIONS - Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi-amine monomer and a multifunctional sulfonyl-containing monomer comprising two or more amine-reactive groups. | 2010-08-05 |
| 20100196306 | BIOACTIVE ANILINE COPOLYMERS - Aniline copolymers and the synthesis thereof for use as antimicrobial (antibacterial, antifungal or antiviral material) material of for the manufacture of antimicrobial objects, suitable for use in the health, food, packaging, water, paint, wood, textile, poultry, glass, paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. The copolymer may be for example (A): where for example R | 2010-08-05 |
| 20100196307 | Attractant for Indian Meal Moth Larve - A composition containing 2-pentylfuran is an effective attractant for the larvae of the Indian meal moth ( | 2010-08-05 |
| 20100196308 | VITAMIN D3 AND ANALOGS THEREOF FOR ALLEVIATING SIDE EFFECTS ASSOCIATED WITH CHEMOTHERAPY - The present disclosure relates to the use of vitamin D compounds, such as vitamin D3, or analogs and/or metabolites thereof, to modulate bone marrow progenitors and stromal cells prior to the administration of antineoplastic agents. The methods of the present disclosure may ameliorate myelosuppression by increasing the availability of pluripotent stem cell progenitors, and can be used in combination with standard therapy (e.g. granulocyte stimulating factor) to increase proliferation of myeloid cells and/or improve their mobilization from the bone marrow, thereby diminishing the dose and administration of colony-stimulating factors (CSFs) as well as the recuperation time following chemotherapy. | 2010-08-05 |
| 20100196309 | INTERLEUKIN-21 VARIANTS WITH ALTERED BINDING TO THE IL-21 RECEPTOR - The invention is concerned with IL-21 polypeptide variants having an altered binding to the common gamma chain (c) of the IL-21 receptor and the use thereof in therapy. | 2010-08-05 |
| 20100196310 | METHODS OF TREATING CANCER BY ADMINISTERING HUMAN IL-18 COMBINATIONS - The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents. | 2010-08-05 |
| 20100196311 | METHODS AND COMPOSITIONS CONTAINING mTOR INHIBITORS FOR ENHANCING IMMUNE RESPONSES - Provided are compositions and methods for enhancing immune responses to an antigen. The compositions contain an isolated population of CD8+T cells and an inhibitor of mammalian target of rapamycin (mTOR). The method for obtaining an enhanced immune response to an antigen in an individual entails administering to the individual the antigen and an inhibitor of mammalian target of rapamycin (mTOR). CD8+T cells may also be used for adoptive cell transfer (ACT) therapy. | 2010-08-05 |
| 20100196312 | GLYCOSYLATED IL-7, PREPARATION AND USES - The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects. | 2010-08-05 |
| 20100196313 | Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture - Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region. | 2010-08-05 |
| 20100196314 | Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture - Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region. | 2010-08-05 |
| 20100196315 | IL-12/p40 BINDING PROTEINS - The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental. | 2010-08-05 |
| 20100196316 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 2010-08-05 |
| 20100196317 | CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES - A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of a cyclosporin compound. | 2010-08-05 |
| 20100196318 | Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab - Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease; and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy. | 2010-08-05 |
| 20100196319 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS - The present invention relates to 4,5-ring annulated indole derivatives of formula (I), compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient, | 2010-08-05 |
| 20100196320 | INTERFERON APLPHA SEQUENTIAL REGIMEN FOR TREATING CANCERS - The present invention relates to a method of treating cancers, especially those showing resistance to classical anti-pro liferative chemotherapy drugs. Further, the invention provides a specific interferon alpha sequential regimen for treating cancers, especially those showing resistance to classical anti-proliferative chemotherapy drugs such as stem cell driven cancers. More specifically, the invention relates to a use of IFN alpha for the preparation of a pharmaceutical formulation for the treatment of cancers wherein the pharmaceutical formulation is to be administered following a sequential administration pattern i.e. an induction period wherein a therapeutically effective amount of IFN alpha is administered, a period during which ni IFN alpha is administrated and a chemotherapy period wherein a therapeutically effective amount of a chemotherapeutic agent is administered. | 2010-08-05 |
| 20100196321 | COMPOUNDS - The present invention features compounds of Formula (I) and (Ia), pharmaceutical compositions and use in the treatment of viral disease: | 2010-08-05 |
| 20100196322 | POLYMER FOR TISSUE ENGINEERING APPLICATIONS AND DRUG DELIVERY - A biocompatible and biodegradable elastomeric polymer material, the polymer material comprising: glycerol and dodecanedioic acid, wherein the molar ratio of glycerol to dodecanedioic acid is from about 5:1 to about 1:5. Methods for using the biocompatible and biodegradable elastomeric polymer material comprises providing an PGD elastomeric polymer comprising glycerol and dodecanedioic acid, in a molar ratio of glycerol to dodecanedioic acid of about 1:1 and administering the PGD elastomeric polymer to a soft tissue defect site in needs thereof. | 2010-08-05 |
| 20100196323 | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof - The invention relates to a probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive, comprising a mixture of microorganisms, selected from the group | 2010-08-05 |
| 20100196324 | MULTIFUNCTIONAL CYTOKINES - The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof. | 2010-08-05 |
| 20100196325 | Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods - Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject for controlling viral titer, are provided. The combination of a therapeutic virus and chemotherapeutic agent can be used in methods of treating diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The combination can also be used as a preventive measure or as a treatment to reduce or eliminate symptoms associated with oncolytic viral therapy. | 2010-08-05 |
| 20100196326 | METHOD AND SYSTEM FOR BIASING CELLULAR DEVELOPMENT - Compositions and methods comprising siRNA targeted to APP mRNA are advantageously used to transfect stem cells and bias the cells against differentiating into glial type neural cells. The siRNA of the invention causes RNAi-mediated silencing of the APP mRNA. The inventors have discovered that expression APP induces gliogenesis, i.e., promotes differentiation of potent cells into glial cells. The transfection of potent cells with the subject siRNA silences APP mRNA and thus increases probability of the cells to differentiate into non-glial neural cells. | 2010-08-05 |
| 20100196327 | METHODS FOR DIAGNOSING BIOLOGICAL SAMPLES CONTAINING STEM CELLS - The present invention relates to a method for diagnosing the compatibility of a biological sample containing stem cells from a donor with the immune system of a recipient. Furthermore, the present invention relates to a method for determining the quality of a stem cell preparation based on the inventive method, as well as methods of diagnosing an immune disorder affecting stem cell recognition. The present invention further relates to a method for producing an improved stem cell preparation, and an apparatus that is equipped for performing the method according to the invention. The invention can be used in the field of stem cell-based transplantation and respective diseases. The invention also includes a method for testing the efficacy of donor immune cells as treatments for disease such as cancer in a host patient. A method for testing the immune response of a patient to recall antigens is also disclosed. | 2010-08-05 |
| 20100196328 | ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION - The invention provides methods for inducing or enhancing neovascularization following ischemia by transplanting an effective amount of human central nervous system stem cells. The human central nervous system stem cells can be grown as neurospheres or in adherent culture. Also provided are methods for inducing the repair of ischemic tissue in a patient and methods for treating stroke in a patient suffering therefrom. | 2010-08-05 |
| 20100196329 | COMPOSITION FOR TREATING ISCHEMIC LIMB DISEASE COMPRISING STEM CELLS DERIVED FROM ADIPOSE TISSUE - Disclosed herein is a cell therapeutic composition for treating ischemic limb diseases, more specifically, disclosed is a cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and sucrose or mannose as an excipient. The composition induces angiogenesis around closed blood vessels in the ischemic limb lesions, and thus is useful to treat ischemic diseases. | 2010-08-05 |
| 20100196330 | PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN AND THERAPEUTICAL USES THEREOF - The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients. | 2010-08-05 |
| 20100196331 | COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS - Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier. | 2010-08-05 |
| 20100196332 | Generation of brachial, thoracic and lumbar spinal motor neurons from embryonic stem cells in the absence of all-trans retinoic acid supplement - Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS). | 2010-08-05 |
| 20100196333 | Device and Process for Producing Fiber Products and Fiber Products Produced Thereby - The present invention is directed to a fiber, preferably bone fiber, having a textured surface, which acts as an effective binding substrate for bone-forming cells and for the induction or promotion of new bone growth by bone-forming cells, which bind to the fiber. Methods of using the bone fibers to induce or promote new bone growth and bone material compositions comprising the bone fibers are also described. The invention further relates to a substrate cutter device and cutter, which are effective in producing substrate fibers, such as bone fibers. | 2010-08-05 |
| 20100196334 | Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site. | 2010-08-05 |
| 20100196335 | Methods and Compositions for Regulated Expressions of Nucleic Acid at Post-Transcriptional Level - The present invention provides an isolated nucleic acid comprising: a) at least one first nucleotide sequence encoding a heterologous nucleotide sequence of interest; and b) at least two second heterologous nucleotide sequences, wherein each second heterologous nucleotide sequences comprises: i) a first set of splice elements defining a first intron that is removed by splicing to produce a first RNA molecule that imparts a biological function in the absence of activity at a second set of splice elements; and ii) the second set of splice elements defining one or more introns different from said first intron, wherein said one or more introns different from said first intron are removed by splicing to produce no RNA molecule and/or a second RNA molecule that docs not impart a biological function, when said second set of splice elements is active. Further provided are methods of using the nucleic acid of this invention to regulate transgene expression. | 2010-08-05 |
| 20100196336 | MODIFIED DENDRITIC CELLS HAVING ENHANCED SURVIVAL AND IMMUNOGENICITY AND RELATED COMPOSITIONS AND METHODS - Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.” | 2010-08-05 |
| 20100196337 | METHODS AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL - The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population. | 2010-08-05 |
| 20100196338 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE - A fusion protein for treating cardiovascular disease includes a transcription factor (TF) and a cell-penetrating peptide (CPP). The fusion protein can be expressed from a cell that is delivered to the tissue being treated. | 2010-08-05 |
| 20100196339 | Microparticle-Based Transfection and Activation of Dendritic Cells - The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles, with the microparticles being comprised of biodegradable polymer and cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide. | 2010-08-05 |
| 20100196340 | LACTID ACID BACTERIA AS PRIOBIOTIC STRAINS AND COMPOSITIONS CONTAINING SAME - Useful probiotics have been selected among lactic acid bacteria strains of the genus | 2010-08-05 |
| 20100196341 | Novel Lactobacillus paracasei subsp. paracasei SG96, a Bacteriostatic Composition Containing the same and Use Thereof | 2010-08-05 |
| 20100196342 | MOOD, MEMORY AND COGNITIVE FUNCTION WITH PYRIDOXAL 5'-PHOSPHATE - This invention relates to improvement of mood, memory and cognitive function with administration of pyridoxal 5′-phosphate. Also provided is the use of pyridoxal 5′-phosphate for the preparation of a medicament for the improvement of mood, memory and cognitive function, and kits comprising pyridoxal 5′-phosphate for the same purpose. | 2010-08-05 |
| 20100196343 | COMPOSITIONS, METHODS, DEVICES, AND SYSTEMS FOR SKIN CARE - Accordingly, a need has arisen for improved compositions, methods, devices, and systems for skin care including, without limitation, topical compositions and phototherapy devices and methods. A skin care method may comprise, in some embodiments, contacting at least a portion of the skin of a subject with a homogeneous, stable, self-foaming composition, illuminating the at least a portion of the skin exclusively with light of a desired wavelength (e.g., from about 390 nm to about 430 nm, and contacting the at least a portion of the skin with an anti-oxidant serum composition. | 2010-08-05 |
| 20100196344 | COMPOSITIONS AND METHODS FOR TREATING PANCREATIC INSUFFICIENCY - The present invention relates to compositions for the treatment of conditions, including pancreatic insufficiency. The compositions of the present invention comprise lipase, protease and amylase in a particular ratio that provides beneficial results in patients, such as those afflicted with pancreatic insufficiency. This invention also relates to methods using such compositions for the treatment of pancreatic insufficiency. | 2010-08-05 |
| 20100196345 | PRODUCTION OF HIGH MANNOSE PROTEINS IN PLANT CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 2010-08-05 |
| 20100196346 | NOVEL SUBSTRATE FOR RPN 11 ENZYMATIC ACTIVITY - The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates. | 2010-08-05 |
| 20100196347 | BONE GRAFTS WITH REDUCED PROTEASE ACTIVITY AND METHODS OF SELECTION AND USE - The invention features bone grafts (such as bone allografts) with reduced protease activity. These bone grafts are useful, for example, in conjunction with a polypeptide of interest (such as platelet derived growth factor) for treating, stabilizing, preventing, and/or delaying a bone, periodontium, ligament, cartilage, or tendon condition in an individual (such as a human). Additionally, the invention provides methods of measuring the protease activity associated with a bone graft, reducing the level of protease activity associated with a bone graft, selecting a bone graft with an acceptable level of protease activity, and methods of administering a bone graft and a polypeptide of interest to an individual. | 2010-08-05 |
| 20100196348 | COMBINATION TREATMENT WITH t-PA VARIANT AND LOW MOLECULAR WEIGHT HEPARIN - The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin. | 2010-08-05 |
| 20100196349 | REELER DOMAIN CONTAINING PROTEIN - This invention relates to protein INSP 171, herein identified as containing a Reeler domain, and to the use of this protein and the nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease. | 2010-08-05 |
| 20100196350 | PHARMACEUTICAL COMPOSITION FOR TREATING CHOLANGIOCARCINOMA, A METHOD FOR INHIBITING GROWTH OR INVASION OF CHOLANGIOCARCINOMA AND A METHOD FOR TREATING CHOLANGIOCARCINOMA - Disclosed herein are a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoiria, comprising a L1CAM activity inhibitor or expression suppressor and a treatment method using the composition. This is based on the finding that L1CAM is overexpressed on cholangiocarcinoma and plays an important role in the growth and metastasis of cholangiocarcinoma and the mortality of cholangiocarcinoma patients increases as the expression rate of L1CAM increases. Also, antibodies inhibitory of the activity of L1CAM, or siRNAs suppressing the expression of L1CAM, are found to reduce the growth and invasion of cholangiocarcinoma cells. Mouse monoclonal antibodies, recognizing the L1CAM protein on the cholangiocarcinoma cell surface and binding specifically to cholangiocarcinoma tissues, or siRNAs, antisense oligonucleotides or shRNAs, may be useful in the treatment of cholangiocarcinoma by inhibiting the growth, invasion and migration of cholangiocarcinoma cell. | 2010-08-05 |
| 20100196351 | SECRETED PATE-LIKE PROTEINS - Novel PATE-like polynucleotides and polypeptides, are provided. Also described are splice-variants resulting in smaller polypeptides including five cysteine residues and capable of forming PATE-like polypeptide multimerse. The described polynucleotides were found to have a surprising expression profile, predominantly in the reproduction system and nervous system. Further provided are pharmaceutical compositions and methods for treatment of various diseases, in particular nervous system disorders, more specifically Alzheimer's disease. | 2010-08-05 |
| 20100196352 | COMPOSITION FOR INCREASING STAMINA - Use of whey protein isolate in the preparation of a composition for increasing mean aerobic capacity, enhanced haemoglobin production, enhanced red blood cell production and increased mean corpuscular haemoglobin concentration in competitive species, such as equine species, involved in strenuous activity. The composition may further comprise a prebiotic such as a fructo-oligosaccharide for example inulin. | 2010-08-05 |
| 20100196353 | INTRADERMAL HPV PEPTIDE VACCINATION - The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration. | 2010-08-05 |
| 20100196354 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE - The present invention relates to methods and compositions for modulating platelet activity by inhibiting or activating glutamate receptors. The invention further relates to preventing or treating thrombotic diseases. | 2010-08-05 |
| 20100196355 | Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity - Immunophilin ligands and their uses as modulators of calcium channel activity are disclosed. Screening, therapeutic and prophylactic methods for conditions associated with calcium channel dysfunction, e.g., neurodegenerative and cardiovascular disorders, are also disclosed. | 2010-08-05 |
| 20100196356 | Tumour Growth Inhibitory Compounds and Methods of their Use - Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL or FL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and is most preferably an immunological treatment and comprises the administration of an antibody to the patient. | 2010-08-05 |
| 20100196357 | Microrna modulators and method for identifying and using the same - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 2010-08-05 |
| 20100196358 | METHOD AND KIT TO PROFILE TUMORS BY BIOMARKER ANALYSES INCLUDING TRANSCRIPTIONAL FACTOR ASSAYS - The present invention is related to a method and kit (or device) for the detection and/or the quantification of biomarkers related to tumorigenesis. Said method is advantageously used to propose or adapt an anti-tumoral therapeutic protocol to be administered to a subject. Furthermore, said method and kit (or device) are a technical platform for the identification of new compounds, which are preferably used at (a) specific step(s) of an anti-tumoral therapeutic protocol. | 2010-08-05 |
| 20100196359 | Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same - The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods. | 2010-08-05 |
| 20100196360 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 2010-08-05 |
| 20100196361 | Method of inhibition of vascular development using an antibody - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders. | 2010-08-05 |
| 20100196362 | Engineering Fc Antibody Regions to Confer Effector Function - The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In particular, the molecules of the invention have an increased effector cell function mediated by a FcγR, such as, but not limited to, ADCC. In one embodiment, the variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention have particular utility in treatment, prevention or management of a disease or disorder, such as cancer, in a sub-population of patients, wherein the target antigen is expressed at low levels in the target cell population, in particular, in patients refractory to treatment with an existing therapeutic antibody due to the low level of target antigen expression on the cancer or associated cells. | 2010-08-05 |
| 20100196363 | CANCER TREATMENT COMBINATION THERAPY COMPRISING VINFLUNINE AND TRASTUZUMAB - The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab. | 2010-08-05 |
| 20100196364 | MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 - The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2010-08-05 |
| 20100196365 | USE OF IMIDAZOQUINOLINES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS - The present invention relates to the use of compounds of formula (I) | 2010-08-05 |
| 20100196366 | Gefitnib Sensitivity-Related Gene Expression and Products and Methods Related Thereto - Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described. | 2010-08-05 |
| 20100196367 | Methods For Screening Candidate Agents For Modulating Prorenin And Renin, Assays for Detecting Prorenin And Antibodies - The present invention relates to antibodies that bind to prorenin. In particular, the invention relates to monoclonal antibodies that bind to prorenin and inhibit the activation of prorenin. The antibodies of the invention are useful for screening for candidate agents that inhibit the activation of prorenin and candidate agents the modulate the activity of renin. The antibodies are also useful as diagnostics and for treating disease states. | 2010-08-05 |
| 20100196368 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE - New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. | 2010-08-05 |
| 20100196369 | METHODS FOR TREATMENT OF FOLLICULAR LYMPHOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2010-08-05 |
| 20100196370 | FUSION PROTEIN OF IMMUNOGLOBULIN FC AND HUMAN APOLIPOPROTEIN(A) KRINGLE FRAGMENT - The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor. | 2010-08-05 |
| 20100196371 | METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES - The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. | 2010-08-05 |
